There are 2185 resources available
376P - Evaluating adherence to oral anticancer medications in metastatic and non-metastatic breast cancer patients
Presenter: Rana El-Shewy
Session: Poster session 15
Resources:
Abstract
1438P - First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW
Presenter: Yoon-Koo Kang
Session: Poster session 18
Resources:
Abstract
377P - Phase II study of trifluridine/tipiracil in pre-treated patients with ER-positive, HER2-negative metastatic breast cancer: A Dutch BOOG (2019-01 TIBET) study
Presenter: Niels Guchelaar
Session: Poster session 15
Resources:
Abstract
1439P - ABBV-400, a c-Met protein–targeting antibody-drug conjugate (ADC), in patients (pts) with advanced gastric/gastroesophageal junction adenocarcinoma (GEA): Results from a phase I study
Presenter: John Strickler
Session: Poster session 18
Resources:
Abstract
378P - Updated data on real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab
Presenter: Duan Yang
Session: Poster session 15
Resources:
Abstract
1440P - Neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma with camrelizumab, albumin-paclitaxel, carboplatin and apatinib (GASTO-1093): A single-arm, open-label, phase II trial.
Presenter: Chao Cheng
Session: Poster session 18
Resources:
Abstract
379P - Safety and efficacy of trastuzumab deruxtecan and concomitant radiation therapy in patients with metastatic breast cancer: A multicentre international retrospective cohort study
Presenter: Luca Visani
Session: Poster session 15
Resources:
Abstract
1441P - Clinical application of a machine learning-based pathomics signature for predicting lymph node metastasis in early gastric cancer
Presenter: Weiyao Li
Session: Poster session 18
Resources:
Abstract
380P - Assessing interstitial lung disease (ILD) risk in metastatic breast cancer (MBC): A comprehensive meta and network analysis of antibody-drug conjugates (ADCs) compared to available treatment options beyond first-line (1L)
Presenter: Linda Cucciniello
Session: Poster session 15
Resources:
Abstract
1442P - Correlation between intratumor HER2 heterogeneity and circulating tumor DNA in HER2 positive advanced gastric cancer: A phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High) substudy
Presenter: Hiroki Osumi
Session: Poster session 18
Resources:
Abstract